Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire all the technology and intellectual property for a novel vaccine, PAS (Polyclonal Antibody Stimulator). PAS functions by stimulating the immune system in the patient to produce endogenous polyclonal antibodies to gastrin, without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy. PAS was discovered at the University of Nottingham and developed by scientists at Aphton Corporation. It was acquired by Receptor Biologix, and then by Cancer Advances. Currently, Cancer Advances is focused on developing PAS therapeutics for gastric, pancreatic and other cancers, and identifying synergy between treatment classes. The company has developed an intellectual property strategy that holds over 100 United States and worldwide patents related to PAS. In addition, Cancer Advances has a trademark portfolio and strategy for pursuing other trademarks.